CHICAGO - TelAve -- Braasch Biotech LLC, an emerging biopharmaceutical company pioneering a new field of anti-somatostatin vaccines, today announced a Notice of Allowance was received from the Japan Patent Office on July 15, 2025,  for Braasch's patent entitled "COMPOSITIONS FOR TREATMENT AND/OR PREVENTION OF MASTITIS."

The Patent Allowance provides claims for the therapeutic and preventative treatments for mastitis in milk production animals. Wherein the milk production animal exhibits significantly increased milk production within days of first vaccination, and does not exhibit loss of muscle mass, increased bone growth, injection site reaction, or hoof problems and decreased use of antibiotics.

The Braasch vaccine technologies, like other veterinary vaccines, utilize specific immunological responses post-vaccination. In the case of the Braasch vaccine, the endogenous hormone somatostatin is targeted. By attenuating the effects of this counter-regulatory hormone, a positive outcome is produced. Unlike other vaccines, the Braasch vaccine's mode of action is by B-cell epitope enhancements which produces an antibody response within 4 days (US Patent 10,441,652 B1, October 2019).

More on TelAve News

• DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies
• CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
• Phinge Explains The Core Safety Principals Of Netverse, Its Patented App-less Platform & Technology Accessed Only Though Its Patented Phones & Devices
• Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
• 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus

"We are pleased that the Japan Patent Office has recognized the vaccine's novelty and commercial utility in the areas of mastitis treatment and milk production enhancement," stated Jeralyn Braasch Haffer, CEO.

Braasch's intellectual property portfolio includes multiple patent families with issued or pending claims directed to utility of anti-somatostatin vaccine technologies, SomatovacÔ for multiple metabolic challenges. These applications relate to both human and veterinary use of the technologies.

About Braasch Biotech

Braasch Biotech is a biopharmaceutical company with a focus on the development and commercialization of innovative products of therapeutic approaches utilizing SomatovacÔ technologies. Currently in the Product Pipeline are vaccines for livestock productivity enhancement, increased fertility, GH/IGF-1 deficiencies and obesity treatment. To date, Braasch has multiple regulatory submissions in progress on the use of vaccines in metabolic regulation of dairy cows, pigs and obese pets. Braasch Biotech is a privately held biopharmaceutical with corporate offices in South Dakota.

For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.